Investors

Early-stage regenerative medicine, cell therapies, organ transplantation, epigenetic reprogramming, AI drug discovery, peptides, and iPSC manufacturing

Multi-sector venture capital with aging-biology investments in senescent-cell therapeutics, canine lifespan extension, epigenetic medicine, stem-cell manufacturing, and engineered organs

Pre-seed and seed investment in longevity biology, AI therapeutics, diagnostics, regenerative medicine, scientific tools, and human performance

Radical life extension technologies including gene therapy, tissue engineering, organ replacement, regenerative medicine, neuroprotection, and healthspan

Longevity company building and early investment across science-based supplements, personalized diagnostics and treatment, preventive health, and healthy-aging services

Longevity, mental health and regenerative medicine; Series A to C investing.

Science-based venture investing with portfolio exposure to cellular rejuvenation, mitochondria and neurodegeneration.

Strategic life-science investment including regenerative cell therapies, neurodegeneration and chronic inflammation.

Healthcare and life-science investing with a documented investment in BioAge Labs and its therapeutics targeting the biology of aging.

Multi-stage healthcare investing with a documented investment in BioAge Labs.

Venture investing with exposure to gene therapy for chronic and age-related diseases and animal health.

Early-stage biotechnology and life sciences, including gene therapy for age-related disease.

Venture investing with exposure to gene therapy for age-related disease and companion-animal health.

Venture investing with documented exposure to age-related disease gene therapy.

Venture investing with exposure to human and companion-animal health through age-related disease gene therapy.

Early-stage precision neuroscience and life-science platforms, including mitochondrial quality control.

Biotechnology venture creation and investing, including regenerative cell therapies.

Broad technology venture capital with a documented investment in epigenetic-reprogramming therapeutics through NewLimit.

Broad venture capital with a documented investment in aging-biology therapeutics through NewLimit.

Science-and-compute investment firm with a documented investment in NewLimit's cellular-reprogramming platform.

Broad venture capital with a documented investment in Junevity's cell-reset and siRNA therapeutics platform.

State-backed venture investment with documented exposure to gene therapies for age-associated and chronic disease through Rejuvenate Bio.

Life-science venture capital with a documented investment in mitochondrial therapeutics for neurodegeneration through NRG Therapeutics.

Corporate venture capital of Merck KGaA, Darmstadt, Germany, with a documented investment in NRG Therapeutics' mitochondrial neurodegeneration pipeline.

Corporate life-science venture investing with a disclosed investment in NRG Therapeutics' mitochondrial programs for Parkinson's disease and amyotrophic lateral sclerosis.

Evergreen life-science venture capital with a disclosed investment in NRG Therapeutics' mitochondrial neurodegeneration pipeline.

Life-science venture capital with a disclosed investment in mitochondrial therapeutics through NRG Therapeutics.

Life-science venture capital with a disclosed investment in Lysoway Therapeutics and its lysosomal clearance programs for neurodegenerative disease.

Early-stage venture investing with disclosed backing of Cambrian Bio and its therapeutics targeting biological drivers of aging.

UK government-owned patient-capital investment with direct life-science exposure to NRG Therapeutics' mitochondrial programs for neurodegenerative disease.

Life-science venture capital and company creation with a disclosed investment in Nura Bio's SARM1 and neuroimmune-regulation programs.

Biotechnology venture capital with a disclosed investment in Nura Bio's neuroprotective SARM1-inhibitor pipeline.

Corporate venture capital with disclosed investments in Nura Bio's SARM1 neuroprotection programs and Rezera's NLRP3-inhibitor portfolio.

Life-science and deep-tech venture capital with a disclosed formation and financing role in TRIMTECH Therapeutics' protein-aggregate degradation platform.

Pfizer's corporate venture-investment group, with a disclosed equity investment in TRIMTECH Therapeutics' protein-aggregate degradation pipeline.

UK growth and early-stage investor with a disclosed equity investment in TRIMTECH Therapeutics' neurodegenerative protein-clearance programs.

Multi-stage venture investing with a disclosed investment in Loyal and its canine longevity-drug programs.

Private investment firm with a documented investment in Loyal's canine healthy-aging and lifespan-extension platform.

Venture investor in consumer and technology companies with a disclosed investment in Cambrian Bio's healthspan-focused therapeutics platform.

Healthcare venture-growth investing with a disclosed investment in BioAge's aging-biology therapeutics for metabolic disease.

Life-sciences investment and company creation with a disclosed investment in BioAge's aging-biology therapeutics.

Amgen's corporate venture-capital function, with a disclosed investment in BioAge's aging-biology therapeutics for metabolic disease.

European life-science venture capital with disclosed investments in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.

Biotherapeutics venture capital with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.

Swedish venture investor with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.

Nordic life-science venture fund with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.

Norwegian healthcare investment company with a disclosed investment in Teitur Trophics' neurodegeneration programs.

Independent nonprofit life-science foundation providing company-creation programs, grants, and convertible funding to early-stage startups.

Life-science venture capital and company creation with a disclosed investment in Nine Square Therapeutics' neurodegeneration programs.

Life-sciences venture capital focused on therapeutics, with documented participation in BioAge Labs' aging-biology therapeutics financing.

Gene-editing biotechnology company with a disclosed equity investment in Primera Therapeutics' mitochondrial-DNA editing platform.

Early-stage venture capital with a disclosed seed investment in Loyal's canine longevity-drug programs.

Venture capital with a disclosed investment in Loyal's canine healthspan and lifespan-extension programs.

Early-stage venture capital with a disclosed investment in NewLimit's epigenetic-reprogramming medicines for age-related disease.

Healthcare investment across company stages with a disclosed investment in BioAge Labs' metabolic-aging therapeutics.

Healthcare venture and growth investing with a disclosed investment in BioAge Labs' metabolic-aging therapeutics.

Growth investment with a life-sciences strategy and a disclosed investment in BioAge Labs' metabolic-aging therapeutics.

Venture-capital and private-equity investing with a disclosed investment in Retro Biosciences' autophagy, cellular-reprogramming and stem-cell programs for age-related disease.

Life-sciences and healthcare investment across public and private biotechnology, with documented participation in BioAge Labs' aging-biology therapeutics financing.

Venture investment in science-driven university startups, with documented participation in BioAge Labs' aging-biology therapeutics financing.

Lilly's global biotechnology investment arm, with documented participation in BioAge Labs' aging-biology therapeutics financing.

Multi-stage venture capital including a Bio + Health practice, with documented participation in BioAge Labs' aging-biology therapeutics financing.

Early-stage venture capital with a disclosed investment in Loyal's canine longevity-drug programs.

Long-term investment management with documented participation in Loyal's canine longevity-drug financing.